Adaptive Biotechnologies Corporation ADPT
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a hematology diagnostics company. Its next catalyst on record is Target discovery agreement: Potential development, commercial, and sales milestone payments up to $877.5 million (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Target discovery agreement — Potential development, commercial, and sales milestone payments up to $877.5 million (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| clonoSEQ | MRD monitoring in lymphoid cancers | sequencing-based diagnostic | Approved |
| Immune Medicine / TCR target discovery | Cancer and autoimmune disorders | TCR/BCR sequencing platform | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.